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Editorial: Of the Fit and the Fat: Mitochondrial
Abnormalities and Type 2 Diabetes Mellitus
Due to our current lifestyle, characterized by low levels of
physical activity and an overconsumption of energy-rich
foods, we are now facing a dramatic worldwide increase in
the prevalence of obesity and type 2 diabetes mellitus (1).
One of the earliest hallmarks of type 2 diabetes is the resis-
tance of peripheral tissues, such as skeletal muscle and liver,
toward the action of the hormone insulin, leading to a re-
duced removal of blood glucose from the circulation. Much
research has been devoted toward unraveling the causal
factors leading to insulin resistance. For skeletal muscle, this
has led to the suggestion that the accumulation of triglyc-
eride—and its intermediates—is causally related to the de-
velopment of insulin resistance. Indeed, both type 2 diabetic
patients (2) and first-degree relatives of these patients, who
have an increased risk to develop diabetes (3, 4), are char-
acterized by increased levels of intramuscular triglycerides.
Moreover, the acute elevation of circulating plasma fatty
acids induces muscular insulin resistance after 2–3 h, paral-
leled by an elevation of intramuscular triglycerides (5, 6). Can
we conclude from these findings that intramuscular fat ac-
cumulation is detrimental to muscular insulin sensitivity?
The negative answer to this question can be deduced from
the finding that endurance-trained athletes, who are highly
insulin sensitive, are also characterized by elevated levels of
intramuscular triglycerides (2). In exercising humans, intra-
muscular triglycerides may actually be essential to fuel the
mitochondria with substrate sources for the formation of
ATP needed for muscle contraction. Considering this, intra-
muscular triglyceride stores may even have been indispens-
able from an evolutionary perspective because it has been
hypothesized that humans evolved into highly capable en-
durance runners when compared with most other species,
and that this running capability may have been instrumental
in the evolution of the human body form (7). However, in our
modern society, the need to run long distances has rapidly
vanished, but the capability to store fat inside muscle cells
has not. As a result, the human body can store excessive
energy not only in the white adipose tissue, but also in
nonadipose tissues such as skeletal muscle.
If intramuscular triglycerides per se are not detrimental to
muscular insulin resistance, what then is the role of these fat
stores in the etiology of insulin resistance? A major metabolic
difference between endurance-trained athletes and type 2
diabetic patients is the oxidative capacity of the skeletal mus-
cle. This has led to the suggestion that actually the interme-
diates of muscular triglyceride metabolism may interfere
with insulin signaling: if a high intramuscular triglyceride
content is not accompanied by a high capacity to oxidize (or
reesterify) this intramuscular fat, intermediates of triglycer-
ide metabolism, such as fatty acyl-coenzyme A or diacyl-
glycerol, may accumulate, whereas these intermediates re-
main low when oxidative capacity is high. Together, this
suggests that oxidative capacity may well be a more impor-
tant factor in the etiology of type 2 diabetes mellitus. In line
with this, it was recently shown that despite similar levels of
intramuscular triglycerides, only type 2 diabetic patients
were characterized by a reduced in vivo mitochondrial func-
tion when compared with age- and body mass index-
matched obese controls (8). This finding does not stand
alone; in the last 5 yr, a reduced mitochondrial function has
been postulated to be a causal factor in the etiology of type
2 diabetes mellitus. Using noninvasive magnetic resonance
spectroscopy, a reduction in ATP synthesis rate accompanied
by higher intramyocellular lipid levels was shown in first-
degree relatives of type 2 diabetes mellitus patients (9). In
addition, two independent studies showed a coordinated
reduction of genes encoding key enzymes in oxidative me-
tabolism and mitochondrial function, which are under the
control of the peroxisome proliferator-activated receptor-
coactivator (PGC1), in human type 2 diabetes (10, 11). Fur-
thermore, aberrations in mitochondrial morphology, i.e.
smaller and damaged mitochondria, were reported in type 2
diabetic patients (12). Jointly, these studies hint toward ab-
normalities in mitochondrial function and/or oxidative ca-
pacity, and the prevailing hypothesis states that this may
lead to the accumulation of fat and its intermediates in skel-
etal muscle, ultimately leading to insulin resistance and type
2 diabetes mellitus. Alternatively, it has been suggested that
mitochondrial dysfunction may in fact be the consequence of
elevated triglyceride levels in skeletal muscle (13, 14).
Notwithstanding the recent findings that favor a major
role of mitochondrial dysfunction in (obesity-induced) type
2 diabetes, several important questions remain to be an-
swered. In the current issue of this journal, Heilbronn et al.
(15) investigated one of these remaining questions, i.e. the
influence of fatness and fitness on markers of mitochondrial
metabolism. A reduced mitochondrial function as reported
in (pre-)diabetes may simply be the result of a more inactive
lifestyle in these subjects, and many of the previous studies
did not account for this confounding factor. Heilbronn et al.
(15) here used an approach in which sedentary, nondiabetic
but overweight/obese male subjects were divided into in-
sulin-sensitive and insulin-resistant groups, based on the
median glucose infusion rate determined using a hyperin-
sulinemic euglycemic clamp. All subjects were selected to be
inactive, and importantly the two groups were indeed sim-
ilar with regard to VO2max, a marker of aerobic fitness, as
well as for age, body mass index (and body fat percentage),
Abbreviations: PGC1, Peroxisome proliferator-activated receptor-
coactivator; UCP3, uncoupling protein-3.
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and fasting glucose levels. The authors found that the mRNA
levels of PGC1, cytochrome oxidase subunit 1, and uncou-
pling protein-3 (UCP3) were significantly lower in insulin-
resistant subjects. UCP3 is a mitochondrial protein that may
be involved in the protection of mitochondria against lipid-
induced oxidative mitochondrial damage. Therefore, a re-
duced UCP3 content in insulin-resistant subjects could in-
dicate that the mitochondria in these subjects are less well
protected against lipid-induced damage, which could ulti-
mately lead to mitochondrial damage (16). PGC1 is a tran-
scriptional coactivator involved in mitochondrial biogenesis
(the new formation of mitochondria). Consistent with its
reduction, protein levels of complexes I and III of the mito-
chondrial electron transport chain and citrate synthase ac-
tivity were significantly lower in insulin-resistant subjects.
Remarkably, no differences in intramyocellular lipid or fatty
acyl-coenzyme A levels were observed between the insulin-
resistant and insulin-sensitive groups, which may suggest
that other fatty acid intermediates like diacylglycerol may be
more closely related to insulin resistance.
What can we learn from these results? At first glance, the
results seem to stress further the importance of mitochon-
drial aberrations in the etiology of type 2 diabetes mellitus.
The fact that aerobic fitness was similar between the groups
suggests that the mitochondrial abnormalities found in the
insulin-resistant groups were not simply due to a more sed-
entary lifestyle, but could really reflect an inherited defect of
insulin-resistant subjects. Alternatively, however, the data
can be interpreted as the mitochondrial aberrations being the
result of the insulin resistance. In that respect, skeletal muscle
mitochondrial function and gene transcription were recently
compared in type 2 diabetic patients and nondiabetic con-
trols at artificially maintained low or high insulin levels (17).
It was found that in type 2 diabetic patients, high insulin
levels reduced the expression of PGC1, citrate synthase, and
cytochrome oxidase subunit 1 and blunted the insulin-stim-
ulated increase in mitochondrial ATP production. Of inter-
est, in the insulin-resistant group of the study of Heilbronn
et al. (15), insulin levels were also significantly elevated com-
pared with the insulin-sensitive group, leaving the possibil-
ity that here also high insulin levels may have been respon-
sible for the observed mitochondrial aberrations. However,
Heilbronn et al. (15) added a second part to their study, in
which they exercise-trained their subjects for 6 wk with four
40-min sessions per week, adding up to some 3 h of exercise
per week. Both the insulin-sensitive and insulin-resistant
groups significantly improved their insulin sensitivity and
aerobic fitness, but no changes in mitochondrial proteins
were detected. The lack of an effect on mitochondrial me-
tabolism may, however, be owing to the power of the study
because strong significant correlations were observed be-
tween the change in aerobic fitness and/or insulin sensitivity
and the protein content of complex III/V of the mitochon-
drial electron transport chain. Although these correlations
could indicate that the exercise-induced enhancement of in-
sulin sensitivity improved mitochondrial metabolism, this is
not very likely given the well-known potent and direct stim-
ulatory effects of endurance training on mitochondrial bio-
genesis (18). Therefore, the strong relation between the
change in protein content of mitochondrial complex III/V
and insulin sensitivity most likely should be interpreted as
a positive effect of improved mitochondrial biogenesis/con-
tent on insulin sensitivity.
Does this imply that we can conclude that mitochondrial
abnormalities lead to type 2 diabetes mellitus? Obviously,
many more, valuable human intervention studies like this
one are required to definitely answer this question. For ex-
ample, it will be valuable to investigate the effect of inter-
ventions with well-characterized insulin-sensitizing proper-
ties acting via nonmitochondrial pathways on mitochondrial
metabolism. Such intervention studies can further unravel if
mitochondrial abnormalities are the cause or consequence of
the insulin-resistant state. In addition, studies are urgently
needed that will pinpoint the exact location of the mitochon-
drial abnormalities, if any. So far, the available data that favor
a role for mitochondria in the etiology of muscular insulin
resistance have used a wide range of methodologies and
techniques to study mitochondrial “metabolism.” These
methodologies range from the simple determination of mi-
tochondrial gene transcripts, mitochondrial protein and
DNA content, enzyme activities, and ex vivo mitochondrial
function in isolated mitochondria to noninvasive measure-
ment of mitochondrial oxidative capacity. All these meth-
odologies address different aspects of mitochondrial metab-
olism, like mitochondrial biogenesis, mitochondrial density,
and mitochondrial function, and the results may be con-
founded by factors like muscle fiber type and blood flow/
perfusion. Therefore, multifaceted studies examining all of
the above-mentioned aspects in relation to insulin sensitivity
are needed. Regardless of the outcome of these studies, we
must hope that the renewed interest for mitochondria in the
research field of type 2 diabetes mellitus will also further
vitalize the promotional and financial actions needed by
government and other public parties to stimulate further
physical activity in the fight against the diabetic epidemic. If
anything, the papers of Heilbronn et al. (15) and many others
before unquestionably show the potency of physical exercise
training to overcome insulin resistance.
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